Study Finds GLP-1 Weight Loss Drug Users Are Moving Less Despite Successful Weight Loss
Reduced Activity Despite Weight Loss
A growing body of research is examining the effects of GLP-1 receptor agonists—a class of drugs that includes Ozempic, Wegovy, Mounjaro, and Zepbound—on patient health outcomes beyond just the numbers on the scale.
Key Findings
Researchers analyzed Fitbit data from users who began taking these medications and found that daily step counts and overall exercise levels declined after starting treatment. Despite achieving successful weight loss, participants were moving significantly less than before.
Health Implications
The findings are particularly concerning because GLP-1 drugs can reduce muscle mass alongside fat mass. Combined with reduced physical activity, this dual effect could compromise long-term health, including:
- Decreased strength and functional capacity
- Reduced metabolic health
- Potential impacts on bone density
Expert Perspective
Health researchers emphasize the importance of combining medication-assisted weight loss with structured exercise programs to preserve lean muscle mass and maintain overall health.